Physician

Padma Venuaopala Reddy, MD

According to 2025 Medicare claims, Padma Reddy, MD (NPI: 1215029400) practices nephrology in the Homosassa Springs, FL market, with the plurality of this provider's patient population coming from Citrus, FL. This provider's primary affiliated billing organization is CITRUS NEPHROLOGY ASSOCIATES INC (NPI: 1528116027; TIN: 593353460) and primary practice location at 34429-7834.

Reddy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 500 traditional Medicare patients, billed 2,595 HCPCS/CPT codes, and received $256,925 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,264 prescription claims across 271 beneficiaries totaling $262,440 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 106 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $566,944 to $256,925. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $409,167 to $262,440. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,292	6,021	$566,944
2016	1,263	5,118	$481,172
2017	1,269	5,190	$656,118
2018	1,051	4,573	$438,446
2019	856	4,230	$403,422
2020	855	4,005	$389,336
2021	738	3,523	$357,565
2022	626	2,847	$305,096
2023	542	2,306	$260,786
2024	500	2,595	$256,925

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	351	2,428	$409,167
2016	345	2,056	$320,907
2017	330	1,975	$301,415
2018	334	1,995	$226,445
2019	292	1,700	$165,913
2020	275	1,486	$161,567
2021	248	1,287	$132,089
2022	249	1,232	$149,820
2023	258	1,207	$197,218
2024	271	1,264	$262,440

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	227	$15,221
2016	N/R	192	$11,587
2017	N/R	157	$10,180
2018	N/R	82	$5,366
2019	N/R	135	$9,095
2020	N/R	149	$7,957
2021	N/R	138	$6,259
2022	N/R	172	$5,060
2023	N/R	162	$4,238
2024	N/R	106	$1,678

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	51	264	$284
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	36	36	$144
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	76	92	$124
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	135	502	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	330	749	$87

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	127	8,100	$146,319
Velphoro	Sucroferric Oxyhydroxide	19	570	$45,886
Lokelma	Sodium Zirconium Cyclosilicate	14	540	$10,988
Sevelamer Carbonate	Sevelamer Carbonate	41	2,024	$5,881
Sps	Sodium Polystyrene Sulfon/Sorb	11	299	$4,158

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	17	$617
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	38	$401
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	36	$396
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$263

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Padma Venuaopala Reddy, MD?

Tedicare shows public-source Medicare data for Padma Venuaopala Reddy, MD (NPI 1215029400), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Padma Venuaopala Reddy, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Padma Venuaopala Reddy, MD?

Padma Venuaopala Reddy, MD is linked to CITRUS NEPHROLOGY ASSOCIATES INC (billing NPI 1528116027) in the available physician profile data.

Does Padma Venuaopala Reddy, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.